Andy Lu

Mr. Andy Lu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

30 December 2025 in Journal of Affective Disorders
Verified
Journal Article
Open access
GLGia Han Le
Gia Han Le
SWSabrina Wong
Sabrina Wong
DJDanica E. Johnson
Danica E. Johnson
ALAndy Lu
Andy Lu
DODiana Orsini
Diana Orsini
RMRoger McIntyre
Roger McIntyre
Ketamine and esketamine exhibit rapid antidepressant effects in persons with treatment-resistant depression (TRD) and bipolar depression (TRBD). However, the synaptic mechanisms governing dose, frequency, and durability of response remain unclear. This review aims to evaluate the dosing parameters, including minimum dose and optimal dosing intervals, that reliably induce or maintain long-term potentiation (LTP) and/or synaptic scaling in humans and preclinical models. A systematic search (database inception to June 2025) was conducted on OVID and PubMed to identify preclinical and clinical studies reporting ketamine-induced clinical symptom changes alongside direct or indirect marker of LTP and/or synaptic scaling. Study selection, quality assessment, and data extraction were conducted by two independent reviewers. Sixty-one clinical and 17 preclinical studies met inclusion criteria. Most clinical studies enrolled persons with TRD, with fewer including TRBD or mixed TRD/TRBD samples. In TRD, a single 0.5 mg/kg intravenous ketamine infusion produced rapid but transient antidepressant effects, peaking at 24-hours and declining over 2-3 days. A similar temporal pattern was observed in TRBD. Early neurophysiological changes emerged within 3-8-hours, consolidated by 24-hours, and were sparsely detected beyond 3-days post-ketamine treatment. Consistent neurophysiological findings were observed in preclinical models. Across clinical trials, twice- versus thrice-weekly dosing yielded comparable four-week outcomes, and weekly maintenance significantly reduced relapse risk. Ketamine may open a plasticity window lasting approximately 2-3 days. Dosing intervals aligned with this window during an acute course of treatment, informed by rapid neurophysiological markers, may optimize antidepressant durability and response while minimizing drug exposure.

8 January 2026 in Schizophrenia Research
Verified
Journal Article
Open access
ACAllyssa Chan
Allyssa Chan
ALAndy Lu
Andy Lu
TMTrisha Menon
Trisha Menon
SWSabrina Wong
Sabrina Wong
KVKyle Valentino
Kyle Valentino
RMRoger McIntyre
Roger McIntyre
Negative symptoms in schizophrenia (SCZ) are core phenomenological characteristics known to affect health-related quality of life (HRQoL) and functioning. This systematic review aims to synthesize extant literature to evaluate/elucidate the effect of negative symptoms on HRQoL and functional outcomes in persons with SCZ, as well as to better understand the association between HRQoL and functional outcomes. A systematic search was conducted from inception to July 24, 2025, using Pubmed, MedLine, Embase, AMED, PsychInfo, and Scopus. All studies were independently screened by three reviewers (A.C., A.L., T.M.). Primary studies reporting on the association between negative symptoms, HRQoL, and/or functional outcomes in persons with SCZ were included. We included 68 relevant studies. Most studies were observational and cross-sectional, while others employed case-control, before-after without control, or randomized controlled trial designs. A consistent, small, negative correlation was observed between the presence and severity of negative symptoms and HRQoL (r = -0.67 to 0.69), as well as functional outcomes (r = -0.85 to 0.63. A slight positive association was found between functional outcomes and HRQoL (r = -0.63 to 0.58). Our findings underscore the significant impact of negative symptoms on critical patient-reported outcomes, including HRQoL and functional outcomes. Notwithstanding their clinical importance, there is limited research on negative symptoms, and more research is needed on treatments that address negative symptoms directly, emphasizing the urgent need for targeted therapeutic development.